| Literature DB >> 32338076 |
Maria Sokratous1, Schottlaender Lucia2, Thomas Bourinaris3, Chrysoula Marogianni1, Marianthi Arnaoutoglou4, Eleni Patrikiou5, Styliani Ralli1, Aikaterini Markou1, Efthimios Dardiotis1, Henry Houlden3, Georgios M Hadjigeorgiou1,6, Georgia Xiromerisiou1.
Abstract
A total of 178 consecutive patients with definite sALS without frontotemporal dementia (FTD) were enrolled in this study, after complete clinical evaluation. A Repeat-Primed Polymerase Chain Reaction (RP-PCR) protocol was applied to detect the G4C2 repeats expansions. In the studied sALS patients, 5.06% (n = 9) carried the C9orf72 mutation. Among carriers, 2/3 of them were females and spinal onset accounted for 78% and bulbar for 22%, while the mean age of onset was about 60 years. Our study showed that the prevalence of C9orf72 repeat expansion in Greek sALS patients is similar to the overall frequency of the mutation in European populations. The pathogenic mutation remains a promising biomarker for genetic testing and targeted treatment.Entities:
Keywords: C9orf72 expansion; Greek cohort; hexanucleotide repeats; sporadic amyotrophic lateral sclerosis
Year: 2020 PMID: 32338076 DOI: 10.1080/21678421.2020.1757115
Source DB: PubMed Journal: Amyotroph Lateral Scler Frontotemporal Degener ISSN: 2167-8421 Impact factor: 4.092